- Home
- ACA vs MIRM Comparison
ACA vs MIRM Comparison
Compare ACA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACA | MIRM |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.7B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACA | MIRM |
|---|---|---|
| Price | $114.19 | $96.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $120.00 | $115.33 |
| AVG Volume (30 Days) | 239.8K | ★ 797.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 121.99 | 74.59 |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $2,883,400,000.00 | $19,138,000.00 |
| Revenue This Year | $4.98 | $26.22 |
| Revenue Next Year | $6.67 | $22.04 |
| P/E Ratio | $26.92 | ★ N/A |
| Revenue Growth | ★ 12.20 | N/A |
| 52 Week Low | $73.93 | $37.83 |
| 52 Week High | $131.00 | $109.28 |
Technical Indicators
Market Signals| Indicator | ACA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 56.37 |
| Support Level | $112.64 | $85.35 |
| Resistance Level | $118.84 | $107.51 |
| Average True Range (ATR) | 3.28 | 3.75 |
| MACD | 1.49 | 0.78 |
| Stochastic Oscillator | 97.80 | 81.77 |
Price Performance
Historical ComparisonAbout ACA Arcosa Inc.
Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.